Fig. 1: Chemical structure of clinical NBTI compounds (BWC0977 and gepotidacin), ciprofloxacin and zoliflodacin. | Communications Biology

Fig. 1: Chemical structure of clinical NBTI compounds (BWC0977 and gepotidacin), ciprofloxacin and zoliflodacin.

From: Structural interactions of BWC0977 with Klebsiella pneumoniae topoisomerase IV and biochemical basis of its broad-spectrum activity

Fig. 1

BWC0977 is composed of a DNA binding moiety, 7-Fluoro-1-methylquinolin-2(1H)-one on the LHS, a central four atom linker and an enzyme binding moiety pyrazino-oxazinone linked to oxazolidinone on the RHS. Gepotidacin is composed of a triazaacenaphthylene on the LHS, a central basic nitrogen linker region and a pyranopyridine on the RHS. Zoliflodacin is composed of GyrB interacting pyrimidinetrione moiety and a methyl-oxazolidine-2-one group attached to benzisoxazole core. Ciprofloxacin is composed of a ketone group that interacts with DNA, a quinolone core and fluorine atom that interacts with gyrase.

Back to article page